Profound Surpasses 2025 TULSA-PRO(TM) Installed Base Goal

Executive Summary

• Profound Medical reported an installed base of 78 TULSA‑PRO® systems as of Dec 31, 2025, surpassing its target of 75 installations.
• The qualified sales pipeline grew to 97 new systems in the “Verify, Negotiate and Contracting” stages at year‑end.
• Management indicated that a larger installed base is expected to drive higher patient treatment rates and increase recurring high‑margin revenue; full Q4 2025 and FY 2025 results are slated for release in February 2026.

Key Details

• Installed Base: 78 TULSA‑PRO® systems worldwide as of Dec 31, 2025 (goal was 75).
• Sales Pipeline: 97 qualified new TULSA‑PRO® systems classified within “Verify, Negotiate and Contracting” stages at year‑end.
• Revenue Outlook: Management expects the expanding installed base to boost patient treatment volumes and recurring revenue streams.
• Upcoming Disclosure: Fourth‑quarter and full‑year 2025 financial results will be released near the end of February 2026.
• Product Portfolio Reminder: Profound also markets Sonalleve®, a CE‑marked platform for uterine fibroids, adenomyosis, bone metastasis pain palliation, desmoid tumors, and osteoid osteoma; it holds approvals in Canada, the U.S., China, and Europe.

Notable Quotes

• “As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high margin recurring revenue,” – Arun Menawat, CEO & Chairman, Profound Medical Corp.